BioCentury | Apr 25, 2011
Emerging Company Profile

Blueprint: Insightful Kinase Inhibitors

Traditional kinase inhibitor screening approaches for cancer have relied on chemical libraries designed to inhibit other targets or treat different diseases. Blueprint Medicines is looking to change that by building a brand new library of...
BioCentury | May 26, 2003
Strategy

Amgen's 'modality' play in Tularik

Over the past few years, Amgen Inc. 's R&D efforts have been weighted toward the D side. The investment has paid off, as AMGN has received FDA approval for three new drugs since the second...
BioCentury | Jan 7, 2002
Strategy

Leveraging assets & ideas

A deal between Cytokinetics Inc. and Exelixis Inc. to establish small molecule compound libraries marks another example of a collaboration where two biotech companies share ideas and competencies in a narrowly defined area that should...
BC Week In Review | Dec 18, 2000
Company News

Amgen, Kinetix deal

AMGN completed its acquisition of Kinetix, which is focused on small molecule inhibitors of protein kinases, for $170 million in stock (see BioCentury, Oct. 23). Amgen Inc. (AMGN), Thousand Oaks, Calif.   Kinetix Pharmaceuticals Inc....
BC Week In Review | Oct 23, 2000
Company News

Amgen, Kinetix deal

AMGN will acquire Kinetix, which is focused on small molecule inhibitors of protein kinases, for $170 million in stock. AMGN said the acquisition will support its in-house rational drug design platform. Amgen Inc. (AMGN), Thousand...
BC Week In Review | Oct 23, 2000
Company News

Amgen management update

(AMGN to acquire Kinetix, B2) Amgen Inc. (AMGN), Thousand Oaks, Calif.   Business: Biopharmaceuticals   Hired: Nick Lydon as VP of small molecule discovery, formerly president and CEO of Kinetix Pharmaceuticals Inc.  ...
BC Extra | Oct 16, 2000
Company News

Amgen to acquire Kinetix

AMGN will acquire Kinetix Pharmaceuticals (Medford, Mass.), which is focused on small molecule inhibitors of protein kinases, for $170 million in stock. AMGN said that the acquisition will support its in-house rational drug design platform....
BC Week In Review | Feb 28, 2000
Company News

Kinetix, Dana-Farber Cancer Institute deal

The partners will evaluate the potential of small molecules to treat prostate cancer by inhibiting Akt, a cellular enzyme that regulates apoptosis. Kinetix will provide research funding and access to its portfolio of Akt inhibitors,...
BC Extra | Feb 23, 2000
Company News

Anti-cancer collaboration

Kinetix (Medford, Mass.) and the Dana-Farber Cancer Institute will evaluate the potential of small molecules to treat prostate cancer by inhibiting Akt, a cellular enzyme that regulates apoptosis. Kinetix will provide research funding and access...
BioCentury | Jan 17, 2000
Emerging Company Profile

Kinetix Pharmaceuticals Inc.

Kinetix Pharmaceuticals Inc. Medford, Mass. Technology: Discovery of protein kinase inhibitors Disease focus: Immunology, asthma, allergy, cancer, inflammation Clinical status: NA Founded: 1997 by Nicholas Lydon Corporate partners: None University collaborators: None Number of employees:...
Items per page:
1 - 10 of 12
BioCentury | Apr 25, 2011
Emerging Company Profile

Blueprint: Insightful Kinase Inhibitors

Traditional kinase inhibitor screening approaches for cancer have relied on chemical libraries designed to inhibit other targets or treat different diseases. Blueprint Medicines is looking to change that by building a brand new library of...
BioCentury | May 26, 2003
Strategy

Amgen's 'modality' play in Tularik

Over the past few years, Amgen Inc. 's R&D efforts have been weighted toward the D side. The investment has paid off, as AMGN has received FDA approval for three new drugs since the second...
BioCentury | Jan 7, 2002
Strategy

Leveraging assets & ideas

A deal between Cytokinetics Inc. and Exelixis Inc. to establish small molecule compound libraries marks another example of a collaboration where two biotech companies share ideas and competencies in a narrowly defined area that should...
BC Week In Review | Dec 18, 2000
Company News

Amgen, Kinetix deal

AMGN completed its acquisition of Kinetix, which is focused on small molecule inhibitors of protein kinases, for $170 million in stock (see BioCentury, Oct. 23). Amgen Inc. (AMGN), Thousand Oaks, Calif.   Kinetix Pharmaceuticals Inc....
BC Week In Review | Oct 23, 2000
Company News

Amgen, Kinetix deal

AMGN will acquire Kinetix, which is focused on small molecule inhibitors of protein kinases, for $170 million in stock. AMGN said the acquisition will support its in-house rational drug design platform. Amgen Inc. (AMGN), Thousand...
BC Week In Review | Oct 23, 2000
Company News

Amgen management update

(AMGN to acquire Kinetix, B2) Amgen Inc. (AMGN), Thousand Oaks, Calif.   Business: Biopharmaceuticals   Hired: Nick Lydon as VP of small molecule discovery, formerly president and CEO of Kinetix Pharmaceuticals Inc.  ...
BC Extra | Oct 16, 2000
Company News

Amgen to acquire Kinetix

AMGN will acquire Kinetix Pharmaceuticals (Medford, Mass.), which is focused on small molecule inhibitors of protein kinases, for $170 million in stock. AMGN said that the acquisition will support its in-house rational drug design platform....
BC Week In Review | Feb 28, 2000
Company News

Kinetix, Dana-Farber Cancer Institute deal

The partners will evaluate the potential of small molecules to treat prostate cancer by inhibiting Akt, a cellular enzyme that regulates apoptosis. Kinetix will provide research funding and access to its portfolio of Akt inhibitors,...
BC Extra | Feb 23, 2000
Company News

Anti-cancer collaboration

Kinetix (Medford, Mass.) and the Dana-Farber Cancer Institute will evaluate the potential of small molecules to treat prostate cancer by inhibiting Akt, a cellular enzyme that regulates apoptosis. Kinetix will provide research funding and access...
BioCentury | Jan 17, 2000
Emerging Company Profile

Kinetix Pharmaceuticals Inc.

Kinetix Pharmaceuticals Inc. Medford, Mass. Technology: Discovery of protein kinase inhibitors Disease focus: Immunology, asthma, allergy, cancer, inflammation Clinical status: NA Founded: 1997 by Nicholas Lydon Corporate partners: None University collaborators: None Number of employees:...
Items per page:
1 - 10 of 12